Several hereditary disorders, particularly those affecting the physiological anticoagulation systems, have been well established as risk factors for venous thromboembolism.
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In the present study, we investigated the prevalence of the following thrombogenic mutations in a Greek-Cypriot population : the G1691 factor V Leiden mutation, the G20210A mutation in the prothrombin gene, and the C677T mutation in the methylenetetrahydrofolate reductase (MTHFR). All three variants have been documented to be significant risk factors for various cardiovascular conditions. Ninety unrelated subjects were screened. For the Leiden mutation, 11 subjects (12.2%) were heterozygous and one (1.1%) was homozygous. Seven subjects (7.8%) were heterozygous for the G20210A variant in prothrombin; no homozygotes were identified. The C677T mutation in MTHFR was found in 40 individuals in the heterozygous state (44.4%), and in 16 individuals in the homozygous state (17.8%). These data demonstrate that Greek-Cypriots have an increased frequency of thrombogenic mutations, and suggest that screening for these mutations should be seriously considered, especially when surgery or pregnancy is planned. This is the first study for the frequency of mutations in risk factors that predispose to thrombophilia on the island of Cyprus. Key Words: factor V&mdash;prothrombin&mdash;methylene&mdash; tetrahydrofolate reductase (MTHFR)&mdash;thrombophilia&mdash;molec&mdash; ular epidemiology Thrombosis is a serious condition, killing hundreds of thousands and debilitating millions each year through myocardial infarction, pulmonary embolism, or stroke. Inherited thrombophilia is a genetically determined tendency to venous thromboembolism. The term reflects the presence of an inherited factor that, per se, predisposes toward thrombosis but that, because of the episodic nature of thrombosis, requires interaction with other factors (inherited or acquired) before onset of the clinical disorder. Mutations in genes encoding proteins that activate coagulation pathways or inactivate anticoagulation mechanisms play an important role in the predisposition to venous thrombosis. Blood coagulation is downregulated by the protein C anticoagulant system ( 1 ) . Protein C is activated on endothelial cells by thrombin bound to thrombomodulin. Together with its cofactor, protein S, activated protein C degrades the activated forms of factors V and VIII. Resistance to activated protein C is considered the most prevalent inherited cause of venous thrombosis (2) . The most common cause of this resistance is a point mutation in the factor V gene (Factor V Leiden) that replaces an arginine residue at position 506 with a glutamine, R506Q (G to A transition at position 1691) (3). This change causes the mutant factor Va to resist proteolysis by activated protein C. The frequency of the Leiden genetic variation is relatively high in white populations (up to 6%) but much lower in African and Asian populations (down to 0%) (4).
Prothrombin (Factor II) is the precursor of thrombin, the final effector of the clotting cascade that leads to the formation of fibrin. Prothrombin potentiates coagulation via positive feedback loops and also promotes anticoagulation by the protein C pathway (5) . A G-to-A mutation at nucleotide 20210, which is the last residue at the 3'untranslated region of the prothrombin gene, has been found to be associated with higher plasma concentrations of prothrombin and a 2.8-fold increased risk of venous thrombosis (6) . The prothrombin 20210 G-to-A mutation carrier frequency is highest among whites of Southern European origin (3%); slightly lower among whites of Northern European origin (1.7%); uncommon among African blacks (0.7%) and very uncommon among persons of Asian origin (0%) (7) . Hyperhomocystinemia also has been shown to be a risk factor for venous thrombosis, among other conditions (8). The most common genetic cause of hyperhomocystinemia is an amino acid substitution in methylenetetrahydrofolate reductase (MTHFR), the enzyme that converts 5,10-methylenetetrahydrofolate to 5-methyltetrahydrofolate, the methyl donor in the conversion of homocysteine to methionine (9) . A point mutation which changes C to T at nucleotide 677 results in the substitution of valine to alanine at position 222 (C677T). The mutant enzyme exhibits reduced activity. Homozygous mutation in MTHFR is associated with a threefold increase in risk for premature cardiovascular disease (10) . The frequency of this genetic variant is relatively high in French Canadian, European, Middle Eastern, and Japanese populations (12-15%), lower in Finnish (5.4%) and Dutch (5.2%) populations, and very low in black populations (1.4%) (11) .
The aim of the present study was to investigate the frequency of mutations Factor V Leiden, prothrombin G20210A, and MTHFR C677T in a Greek-Cypriot population.
MATERIALS AND METHODS .
Population and DNA Extraction DNA was extracted from whole blood according to standard procedures (12) . The analysis was performed on 90 unrelated DNA samples (180 chromosomes) of Greek-Cypriot origin from our DNA bank.
PCR Reactions
For amplification of the regions of interest on the Factor V, Factor II and MTHFR genes, the following primers were used:
Factor V-F: GGAACAACACCATGATCAGAGCA Factor V-R: TAGCCAGGAGACCTAACATGTTC Factor II-F: GCACAGACGGCTGTTCTCTT Factor II-R: ATAGCACTGGGAGCATTGAAGC MTHFR-F: TGAAGGAGAAGGTGTCTGCGGGA MTHFR-R: AGGACGGTGCGGTGAGAGTG DNA samples were amplified in 20 uL reaction mixtures containing 10 mmol/L Tris (pH 8.3), 50 mmol/L KCl, 1.5 mmol/L MgC'2, 200 umol/L deoxynucleoside triphosphates (dNTPs), 500 nmol/L of each of the two primers, and 1 unit thermostable DNA polymerase (Taq Express, GENPAK Ltd, Brighton, UK). The temperature cycling protocols for each of the three genes consisted of the following steps:
Factor V: denaturation at 93°C for 60 sec, annealing at 62°C for 30 sec, and extension at 68°C for 90 sec. The cycling was repeated 30 times. Factor II: denaturation at 94°C for 30 sec, annealing at 55° C for 15 sec, extension at 68°C for 60 sec. The cycling was repeated 35 times. Methylenetetrahydrofolate reductase: denaturation at 93°C for 50 sec, annealing at 55°C for 50 sec, extension at 68°C for 30 sec. The cycling was repeated 35 times.
Each one of the above polymerase chain reactions (PCRs) was initiated with a 5-minute denaturation at 94°C and terminated with a 5-minute extension at 68°C.
Restriction Enzyme Digestion
For genotype analysis, the 287-bp Factor V, 506-bp Factor II, and 198-bp MTHFR PCR products were digested by adding 5 units of Mnll, Hind III, and Hinfl, respectively, to 5 RL PCR product. The reactions were incubated overnight at 37°C and the digestion products were subsequently separated by electrophoresis on a 6% polyacrylamide gel.
The wild-type Factor V fragment contains two Mnll sites, resulting in fragments of 157, 93, and 37 bp. The G1691A mutation abolishes one of the two Mnll sites, and, as a result, digestion of the 1691A (mutated) product gives rise to fragments of 157 and 130 bp.
The normal factor II PCR product contains one HindIII site, and digestion gives fragments of 406 bp and 100 bp. The G20210A mutation creates a second site for the HindIII resulting in 383 bp, 100 bp, and 23 bp fragments after digestion. The wild-type MTHFR fragment contains no Hinfl sites, whereas the 677T (mutated) product contains one site, and digestion using this enzyme results in fragments of 175 and 23 bp.
RESULTS
DNA samples from 90 unrelated individuals were analyzed for the presence of the following mutations: G1691A in factor V, G20210A in prothrombin, and C677T in MTHFR. The results are presented in Table 1 . Of the 90 subjects, 11 (12.2%) were heterozygous for the G to A transition at nucleotide 1691 of factor V gene, and one ( 1.1 %) had the mutation in the homozygous state (1691AA). In total, 12 individuals had the A variant at this position (13.3%), and the mutant allele frequency was 7.2% (13/180). Seven individuals (7.8%) were heterozygous for the G20210A variant in prothrombin ; no homozygotes were identified. The mutant allele frequency was 3.9%. The C677T mutation in MTHFR was found in 40 individuals in the heterozygous (44.4%), and in 16 individuals in the homozygous state (17.8%). The mutant allele frequency reached 40% (72/180). Of the 90 subjects, none had a mutation in both factor V and prothrombin at the same time; four (4.4%) had a mutation in both prothrombin and MTHFR; and seven (7.8%) had a mutation in factor V and MTHFR at the same time (Table 2 ). Of the four subjects bearing a mutation in both prothrombin and MTHFR, two were homozygous for the MTHFR variant, whereas of the seven with a mutation in both factor V and MTHFR, only one was homozygous for the MTHFR variant.
DISCUSSION
Venous thrombosis is common in Europeans, whereas it appears to be rare among individuals of other ethnic backgrounds. This could be attributed to either genetic or environmental factors, or both. The assessment of factors that predispose to thrombophilia is important for the prevention of venous thromboembolic disease. In the present study, the frequency of genetic variants in thrombophilia risk factors was investigated for the first time in Greek-Cypriots.
For Factor V, the severity of resistance to activated protein C correlates with the homozygous and heterozygous genotypes. Heterozygotes for factor V Leiden have a sevenfold increased risk for venous thromboembolism, whereas homozygotes are eight times more susceptible (4) . The literature reports numerous heterozygotes and very few homozygotes. In agreement to this, in our study, 12.2% of the population were heterozygous and 1.1 % were homozygous for the Leiden mutation. The mutant allele frequency (7.2%) was found to be 2.2 times higher than the one reported for the rest of the Europeans (3.2%) (4).
The prevalence of the prothrombin G20210A mutation in the Cypriot population was 7.8%, which is 2.6 times higher than the one reported in Southern Europeans (3%) (7) . The prevalence of this mutation in Greek-Cypriots is even higher than the one in patients with an objectively confirmed history of venous thrombosis in a UK clinic (5.5%) (13) . Heterozygosity for the 20210A allele was reported to be associated with a 2.8-fold increase in relative risk for venous thrombosis (6) . Homozygous mutation in MTHFR is associated with a threefold increase in risk for premature cardiovascular disease (10) . Of the study population, 44% were heterozygous and 17.8% were homozygous for the MTHFR 677T variant. The frequency of the homozygous state found in our study is slightly increased compared with French Canadian, European, Middle Eastern, and Japanese populations (12% to 15%), but it is significantly higher than the frequencies reported in Finnish (5.4%), Dutch (5.2%), and black populations (1.4%) (11) . Different studies have suggested that the combination of homozygous MTHFR-thermolability and heterozygous factor V-R506Q exerts an increased risk of thrombosis (14, 15) . When our study population was investigated for combined abnormalities, we found that of our subjects, none had a mutation in both factor V and prothrombin at the same time; 4.4% had a mutation in both prothrombin and MTHFR; and 7.8% had a mutation in factor V and MTHFR at the same time. Of the 90 individuals, 50 (55.6%) had a mutation in either factor V or prothrombin or MTHFR alone, and only one ( 1.1 %) had a mutation in all three factors at the heterozygous state. Seligsohn and Zivelin (16) demonstrated that combined thrombogenic defects lead to excessive thrombosis, and suggested that in asymptomatic subjects with a combined defect, strict prophylactic measures should be taken in circumstances potentially leading to thrombosis.
Altogether, 68.9% of the general population on the island of Cyprus was found to have at least one underlying defect. These findings demonstrate that the prevalence of genetic defects in risk factors that predispose to thrombophilia is higher in Cypriots compared with populations of other ethnic backgrounds. This could be the result of a selective advantage. As suggested by Rees et al. (4) , thrombophilia may have been less damaging in the past when risk factors associated with today's lifestyle, eg, smoking, estrogen therapy, oral contraceptives, and surgery were rare. The heterozygous state may be advantageous to reproductively active women, as it could result in reduced menstrual blood loss, thus protecting against iron deficiency. Furthermore, as proposed by Rees et al. (4) , carrier status might cause reduced bleeding after trauma. This is the first molecular epidemiology report examining three of the most important genetic risk factors for thrombophilia in the Greek Cypriot population. The results show high frequency of these genetic variants in Cyprus, suggesting that screening for these mutations should be seriously considered, especially when surgery is planned. Screening may also be considered in case of pregnancy, because mutations predisposing to thrombosis are important risk factors for obstetrical complications related to inadequate maternal-fetal circulation (17) . Patients with thrombophilia should be considered at high risk for thromboembolism and should receive ap-propriate prophylaxis according to the clinical setting. Therefore, it is important for the medical profession to know the epidemiology and to be familiar with the diagnostic methodology and definition of high risk groups, in order to apply appropriate prophylaxis and treat early deep vein thrombosis effectively.
